Confirmed
Two or more controlled phase 3 trials met their main goal.
Integrin blockade (lymphocyte trafficking): reduce relapses and new lesions in relapsing MS
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
relapsing MS · Integrin blockade (lymphocyte trafficking)
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 24
- Running now
- 0
- Controlled phase 2/3 trials
- 9
- People in controlled trials
- 3643
Deciding trials (phase 3): 3 met, 0 did not.
Other linked trials: 21
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
- Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosisdecides the statusMet main goal
Phase 3 · 2002 · Placebo-controlled · MSFT-NCT00030966
Combination therapy resulted in a 24 percent reduction in the relative risk of sustained disability progression (hazard ratio, 0.76; 95 percent confidence interval, 0.61 to 0.96; P=0.02).
Read by software from the paper's abstract - Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosisdecides the statusMet main goal
Phase 3 · 2001 · Placebo-controlled · MSFT-NCT00027300
Natalizumab reduced the risk of sustained progression of disability by 42 percent over two years (hazard ratio, 0.58; 95 percent confidence interval, 0.43 to 0.77; P<0.001).
Read by software from the paper's abstract Phase 2/3 · 2010 · Placebo-controlled · MSFT-NCT01440101
Other linked trials: 21
These linked trials do not set the status.
- A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)Stopped, other reason
Phase 4 · 2023 · Not randomised
- SUPERNEXTResult in a paper, not read yet
Phase 4 · 2020 · Not randomised
- A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of NatalizumabResult in a paper, not read yet
Phase 4 · 2019 · Not randomised
- NTZ2TTYNo result found
Phase 4 · 2019 · Placebo-controlled
- PDNMSNo result found
Phase 4 · 2016 · Not randomised
- NAPPREMSNo result found
Phase 4 · 2015 · Not randomised
- REVEALStopped, other reason
Phase 4 · 2014 · Compared with fingolimod
- ESCALATEStopped, other reason
Phase 4 · 2014 · Not randomised
Phase 3 · 2022 · Not randomised
- AntelopeNo result found
Phase 3 · 2019 · Compared with natalizumab
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Status changed from Results pending to Confirmed
- 2026-10-28Trials: 25 → 24
- 2026-10-28Status changed from Being tested to Results pending
- 2026-10-27First listed as Being tested
Related hypotheses
- Integrin blockade (lymphocyte trafficking): reduce relapses and new lesions in early MS (CIS or RIS)
- Integrin blockade (lymphocyte trafficking): reduce relapses and new lesions in relapsing and progressive MS
- Integrin blockade (lymphocyte trafficking): reduce relapses and new lesions in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error